The success of non-ABO-identical convalescent plasma transfusion in coronavirus disease 2019 (COVID-19) related acute respiratory distress syndrome (CARDS): a case-report

Abstract

Coronavirus disease 2019 (COVID-19) is pandemic with substantial fatality without specific treatment. Convalescent plasma is used to treat infectious diseases including severe acute respiratory syndrome coronavirus 1 and Middle East respiratory syndrome coronavirus infection, because of the effect of direct neutralizing and suppression of viremia, and immunomodulation effect. Although several anti-cytokine agents were suggested to improve outcomes of the patient, the unavailability of drugs will be a major problem for accessing. We reported the experience of convalescent plasma transfusion for COVID-19 related acute respiratory distress syndrome (CARDS), who refractory to standard treatment and clinically improvement after convalescent plasma transfusion, despite unidentical blood group.